Emodin blocks the SARS coronavirus spike protein and angiotensin-converting enzyme 2 interaction

Antiviral Research

Volumn 74, Issue 2, 2007, Pages 92-101

  Ho, Tin Yun ^a   Wu, Shih Lu ^a   Chen, Jaw Chyun ^a   Li, Chia Cheng ^a   Hsiang, Chien Yun ^a  

^a CHINA MEDICAL UNIVERSITY   (Taiwan)

Author keywords

Angiotensin converting enzyme 2; Emodin; SARS coronavirus; Spike protein

Indexed keywords

ANGIOTENSIN CONVERTING ENZYME 2; CHRYSIN; DIPEPTIDYL CARBOXYPEPTIDASE; EMODIN; RHEIN; UNCLASSIFIED DRUG; VIRUS PROTEIN; VIRUS SPIKE PROTEIN;

ANGIOSPERM; ANIMAL CELL; ANTIVIRAL ACTIVITY; ARTICLE; BIOTINYLATION; CHEMICAL STRUCTURE; CHINESE HERB; DOSE RESPONSE; DRUG MECHANISM; ENZYME LINKED IMMUNOSORBENT ASSAY; HERB; MEDICINAL PLANT; NONHUMAN; POLYGONUM MULTIFLORUM; PRIORITY JOURNAL; PROTEIN PROCESSING; PROTEIN PROTEIN INTERACTION; PROTEIN PURIFICATION; RHUBARB; SARS CORONAVIRUS; SEVERE ACUTE RESPIRATORY SYNDROME; VERO CELL;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; ANTIVIRAL AGENTS; CERCOPITHECUS AETHIOPS; CORONAVIRUS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUGS, CHINESE HERBAL; EMODIN; MEMBRANE GLYCOPROTEINS; PEPTIDYL-DIPEPTIDASE A; PLANTS, MEDICINAL; POLYGONUM; RETROVIRIDAE; RHEUM; SARS VIRUS; VERO CELLS; VIRAL ENVELOPE PROTEINS;

CORONAVIRUS; POLYGONACEAE; POLYGONUM; POLYGONUM MULTIFLORUM; RHEUM; RHEUM OFFICINALE; SARS CORONAVIRUS;

EID: 33947221383     PISSN: 01663542     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.antiviral.2006.04.014     Document Type: Article

References (54)

1. Agarwal S.K., Singh S.S., Verma S., and Kumar S. Antifungal activity of anthraquinone derivatives from Rheum emodi. J. Ethnopharmacol. 72 (2000) 43-46
2. Alves D.S., Pe′rez-Fons L., Estepa A., and Micol V. Membrane-related effects underlying the biological activity of the anthraquinones emodin and barbaloin. Biochem. Pharmacol. 68 (2004) 549-561
3. Arosio B., Gagliano N., Fusaro L.M., Parmeggiani L., Tagliabue J., Galetti P., DeCastri D., Moscheni C., and Annoni G. Aloe-Emodin quinone pretreatment reduces acute liver injury induced by carbon tetrachloride. Pharmacol. Toxicol. 87 (2000) 229-233
4. Barnard D.L., Huffman J.H., Morris J.L.B., Wood S.G., Hughes B.G., and Sidwell R.W. Evaluation of the antiviral activity of anthraquinones, anthrones and anthraquinone derivatives against human cytomegalovirus. Antiviral Res. 17 (1992) 63-77
5. Battistutta R., Sarno S., DeMoliner E., Papinutto E., Zanotti G., and Pinna L.A. The replacement of ATP by the competitive inhibitor emodin induces conformational modifications in the catalytic site of protein kinase CK2. J. Biol. Chem. 275 (2000) 29618-29622
6. Bosch B.J., van der Zee R., de Haan C.A., and Rottier P.J. The coronavirus spike protein is a class I virus fusion protein: structural and functional characterization of the fusion core complex. J. Virol. 77 (2003) 8801-8811
7. Chan K.S., Lai S.T., Chu C.M., Tsui E., Tam C.Y., Wong M.M., Tse M.W., Que T.L., Peiris J.S., Sung J., Wong V.C., and Yuen K.Y. Treatment of severe acute respiratory syndrome with lopinavir/ritonavir: a multicentre retrospective matched cohort study. Hong Kong Med. J. 9 (2003) 399-406
8. Chen F., Chan K.H., Jiang Y., Kao R.Y., Lu H.T., Fan K.W., Cheng V.C., Tsui W.H., Hung I.F., Lee T.S., Guan Y., Peiris J.S., and Yuen K.Y. In vitro susceptibility of 10 clinical isolates of SARS coronavirus to selected antiviral compounds. J. Clin. Virol. 31 (2004) 69-75
9. Chen Y.C., Shen S.C., Lee W.R., Hsu F.L., Lin H.Y., Ko C.H., and Tseng S.W. Emodin induces apoptosis in human promyeloleukemic HL-60 cells accompanied by activation of caspase 3 cascade but independent of reactive oxygen species production. Biochem. Pharmacol. 64 (2002) 1713-1724
10. Chen Z., Zhang L., Qin C., Ba L., Yi C.E., Zhang F., Wei Q., He T., Yu W., Yu J., Gao H., Tu X., Gettie A., Farzan M., Yuen K.Y., and Ho D.D. Recombinant modified vaccinia virus Ankara expressing the spike glycoprotein of severe acute respiratory syndrome coronavirus induces protective neutralizing antibodies primarily targeting the receptor binding region. J. Virol. 79 (2005) 2678-2688
11. Cinatle Jr. J., Michaelis M., Hoever G., Preiser W., and Doerr H.W. Development of antiviral therapy for severe acute respiratory syndrome. Antiviral Res. 66 (2005) 81-97
12. Cinatl Jr. J., Morgenstern B., Bauer G., Chandra P., Rabenau H., and Doerr H.W. Glycyrrhizin, an active component of liquorice roots, and replication of SARS-associated coronavirus. Lancet 361 (2003) 2045-2046
13. Cinatl Jr. J., Morgenstern B., Bauer G., Chandra P., Rabenau H., and Doerr H.W. Treatment of SARS with human interferons. Lancet 362 (2003) 293-294
14. Drosten C., Gunther S., Preiser W., van der Werf S., Brodt H.R., Becker S., Rabenau H., Panning M., Kolesnikova L., Fouchier R.A., Berger A., Burguiere A.M., Cinatl J., Eickmann M., Escriou N., Grywna K., Kramme S., Manuguerra J.C., Muller S., Rickerts V., Sturmer M., Vieth S., Klenk H.D., Osterhaus A.D., Schmitz H., and Doerr H.W. Identification of a novel coronavirus in patients with severe acute respiratory syndrome. N. Engl. J. Med. 348 (2003) 1967-1976
15. Fouchier R.A., Kuiken T., Schutten M., van Amerongen G., van Doornum G.J.J., van den Hoogen B.G., Peiris M., Lim W., Stohr K., and Osterhaus A.D.M.E. Koch's postulates fulfilled for SARS virus. Nature 423 (2003) 240
16. Greenough T.C., Babcock G.J., Roberts A., Hernandez H.J., Thomas W.D., Coccia J.A., Graziano R.F., Srinivasan M., Lowy I., Finberg R.W., Subbarao K., Vogel L., Somasundaran M., Luzuriaga K., Sullivan J.L., and Ambrosino D.M. Development and characterization of a severe acute respiratory syndrome-associated coronavirus-neutralizing human monoclonal antibody that provides effective immunoprophylaxis in mice. J. Infect. Dis. 191 (2005) 507-514
17. Guerra B., and Issinger O.G. Protein kinase CK2 and its role in cellular proliferation, development and pathology. Electrophoresis 20 (1999) 391-408
18. Ho T.Y., Wu S.L., Chen J.C., Wei Y.C., Cheng S.E., Chang Y.H., Liu H.J., and Hsiang C.Y. Design and biological activities of novel inhibitory peptides for SARS-CoV spike protein and angiotensin-converting enzyme 2 interaction. Antiviral Res. 69 (2006) 70-76
19. Ho T.Y., Wu S.L., Cheng S.E., Wei Y.C., Huang S.P., and Hsiang C.Y. Antigenicity and receptor-binding ability of recombinant SARS coronavirus spike protein. Biochem. Biophys. Res. Commun. 313 (2004) 938-947
20. Hofmann H., Hattermann K., Marzi A., Gramberg T., Geiner M., Krumbiegel M., Kuate S., Uberla K., Niedrig M., and Pohlmann S.H. S protein of severe acute respiratory syndrome-associated coronavirus mediates entry into hepatoma cell lines and is targeted by neutralizing antibodies in infected patients. J. Virol. 78 (2004) 6134-6142
21. Hofmann H., Geier M., Marzi A., Krumbiegel M., Peipp M., Fey G.H., Gramberg T., and Pohlmann S. Susceptibility to SARS coronavirus S protein-driven infection correlates with expression of angiotensin converting enzyme 2 and infection can be blocked by soluble receptor. Biochem. Biophys. Res. Commun. 319 (2004) 1216-1221
22. Hsiang C.Y., Hsieh C.L., Wu S.L., Lai I.L., and Ho T.Y. Inhibitory effect of anti-pyretic and anti-inflammatory herbs on herpes simplex virus replication. Am. J. Chin. Med. 29 (2001) 459-467
23. Hsiang C.Y., Wu S.L., and Ho T.Y. Morin inhibited 12-O-tetradecanoylphorbol-13-acetate-induced hepatocellular transformation via activator protein 1 signaling pathway and cell cycle progression. Biochem. Pharmacol. 69 (2005) 1603-1611
24. Huang H.C., Chu S.H., and Chao P.D. Vasorelaxants from Chinese herbs, emodin and scoparone, possess immunosuppressive properties. Eur. J. Pharmacol. 198 (1991) 211-213
25. Konoshima T., Kozuka M., Koyama J., Okatani T., and Tagahara K. Studies on inhibitors of skin tumor promotion. VI. Inhibitory effects of quinones on Epstein-Barr virus activation. J. Nat. Prod. 52 (1989) 987-995
26. Koyama J., Morita I., Kawanishi K., Tagahara K., and Kobayashi N. Capillary electrophoresis for simultaneous determination of emodin, chrysophanol, and their 8-beta-d-glucosides. Chem. Pharm. Bull. (Tokyo) 51 (2003) 418-420
27. Koyama M., Kelly T.R., and Watanabe K.A. Novel type of potential anticancer agents derived from chrysophanol and emodin. Some structure-activity relationship studies. J. Med. Chem. 31 (1988) 283-284
28. Ksiazek T.G., Erdman D., Goldsmith C.S., Zaki S.R., Peret T., Emery S., Tong S., Comer J.A., Lim W., Rollin P.E., Dowell S.F., Ling A., Humphrey C.D., Shieh W., Guarner J., Paddock C.D., Rota P., Fields B., DeRisi J., Yang J., Cox N., Hughes J.M., LeDuc J.W., Bellini W.J., and Anderson L.J. A novel coronavirus associated with severe acute respiratory syndrome. N. Engl. J. Med. 348 (2003) 1953-1966
29. Kumar A., Dhawan S., and Aggarwal B.B. Emodin (3-methyl-1,6,8-trihydroxyanthraquinone) inhibits TNF-induced NF-κB activation, IκB degradation, and expression of cell surface adhesion proteins in human vascular endothelial cells. Oncogene 17 (1998) 913-918
30. Li W., Moore M.J., Vasilieva N., Sui J., Wong S.K., Berne M.A., Somasundaran M., Sullivan J.L., Luzuriaga K., Greenough T.C., Choe H., and Farzan M. Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus. Nature 426 (2003) 450-454
31. Lin C.W., Tsai F.J., Tsai C.H., Lai C.C., Wan L., Ho T.Y., Hsieh C.C., and Chao P.D. Anti-SARS coronavirus 3C-like protease effects of Isatis indigotica root and plant-derived phenolic compounds. Antiviral Res. 68 (2005) 36-42
32. Marra M.A., Jones S.J., Astell C.R., Holt R.A., Brooks-Wilson A., Butterfield Y.S., Khattra J., Asano J.K., Barber S.A., Chan S.Y., Cloutier A., Coughlin S.M., Freeman D., Girn N., Griffith O.L., Leach S.R., Mayo M., McDonald H., Montgomery S.B., Pandoh P.K., Petrescu A.S., Robertson A.G., Schein J.E., Siddiqui A., Smailus D.E., Stott J.M., Yang G.S., Plummer F., Andonov A., Artsob H., Bastien N., Bernard K., Booth T.F., Bowness D., Czub M., Drebot M., Fernando L., Flick R., Garbutt M., Gray M., Grolla A., Jones S., Feldmann H., Meyers A., Kabani A., Li Y., Normand S., Stroher U., Tipples G.A., Tyler S., Vogrig R., Ward D., Watson B., Brunham R.C., Krajden M., Petric M., Skowronski D.M., Upton C., and Roper R.L. The Genome sequence of the SARS-associated coronavirus. Science 300 (2003) 1399-1404
33. Moore M.J., Dorfman T., Li W., Wong S.K., Li Y., Kuhn J.H., Coderre J., Vasilieva N., Han Z., Greenough T.C., Farzan M., and Choe H. Retroviruses pseudotyped with the severe acute respiratory syndrome coronavirus spike protein efficiently infect cells expressing angiotensin-converting enzyme 2. J. Virol. 78 (2004) 10628-10635
34. Nonaka G., Minami M., and Nishioka I. Studies on rhubarb (Rhei rhizoma). III. Stilbene glycosides. Chem. Pharm. Bull. (Tokyo) 25 (1977) 2300-2305
35. Peiris J.S.M., Lai S.T., Poon L.L.M., Guan Y., Yam L.Y.C., Lim W., Nicholls J., Yee W.K.S., Yan W.W., Cheung M.T., Cheng V.C.C., Chan K.H., Tsang D.N.S., Yung R.W.H., Ng T.K., Yuen K.Y., and Members of the SARS Study Group. Coronavirus as a possible cause of severe acute respiratory syndrome. Lancet 361 (2003) 1319-1325
36. Petit C.M., Melancon J.M., Chouljenko V.N., Colgrove R., Farzan M., Knipe D.M., and Kousoulas K.G. Genetic analysis of the SARS-coronavirus spike glycoprotein functional domains involved in cell-surface expression and cell-to-cell fusion. Virology 341 (2005) 215-230
37. Rota P.A., Oberste M.S., Monroe S.S., Nix W.A., Campagnoli R., Icenogle J.P., Penaranda S., Bankamp B., Maher K., Chen M.H., Tong S., Tamin A., Lowe L., Frace M., DeRisi J.L., Chen Q., Wang D., Erdman D.D., Peret T.C., Burns C., Ksiazek T.G., Rollin P.E., Sanchez A., Liffick S., Holloway B., Limor J., McCaustland K., Olsen-Rasmussen M., Fouchier R., Gunther S., Osterhaus A.D., Drosten C., Pallansch M.A., Anderson L.J., and Bellini W.J. Characterization of a novel coronavirus associated with severe acute respiratory syndrome. Science 300 (2003) 1394-1399
38. Schinazi R.F., Chu C.K., Babu J.R., Oswald B.J., Saalmann V., Cannon D.L., Eriksson B.F.H., and Nasr M. Anthraquinones as a new class of antiviral agents against human immunodeficiency virus. Antiviral Res. 13 (1990) 265-272
39. Simmons G., Reeves J.D., Rennekamp A.J., Amberg S.M., Piefer A.J., and Bates P. Characterization of severe acute respiratory syndrome-associated coronavirus (SARS-CoV) spike glycoprotein-mediated viral entry. Proc. Natl. Acad. Sci. U.S.A. 101 (2004) 4240-4245
40. Sui J., Li W., Murakami A., Tamin A., Matthews L.J., Wong S.K., Moore M.J., Tallarico A.S., Olurinde M., Choe H., Anderson L.J., Bellini W.J., Farzan M., and Marasco W.A. Potent neutralization of severe acute respiratory syndrome (SARS) coronavirus by a human mAb to S1 protein that blocks receptor association. Proc. Natl. Acad. Sci. U.S.A. 101 (2004) 2536-2541
41. Sui J., Li W., Roberts A., Matthews L.J., Murakami A., Vogel L., Wong S.K., Subbarao K., Farzan M., and Marasco W.A. Evaluation of human monoclonal antibody 80R for immunoprophylaxis of severe acute respiratory syndrome by an animal study, epitope mapping, and analysis of spike variants. J. Virol. 79 (2005) 5900-5906
42. Sydiskis R.J., Owen D.G., Lohr J.L., Rosler K.H.A., and Blomster R.N. Inactivation of enveloped viruses by anthraquinones extracted from plants. Antimicrob. Agents Chemother. 35 (1991) 2463-2466
43. Tan E.L., Ooi E.E., Lin C.Y., Tan H.C., Ling A.E., Lim B., and Stanton L.W. Inhibition of SARS coronavirus infection in vitro with clinically approved antiviral drugs. Emerg. Infect. Dis. 10 (2004) 581-586
44. Tan Y.J., Lim S.G., and Hong W. Characterization of viral proteins encoded by the SARS-coronavirus genome. Antiviral Res. 65 (2005) 69-78
45. Tripet B., Howard M.W., Jobling M., Holmes R.K., Holmes K.V., and Hodges R.S. Structural characterization of the SARS-coronavirus spike S fusion protein core. J. Biol. Chem. 279 (2004) 20836-20849
46. Wu C.J., Jan J.T., Chen C.M., Hsieh H.P., Hwang D.R., Liu H.W., Liu C.Y., Huang H.W., Chen S.C., Hong C.F., Lin R.K., Chao Y.S., and Hsu J.T. Inhibition of severe acute respiratory syndrome coronavirus replication by niclosamide. Antimicrob. Agents Chemother. 48 (2004) 2693-2696
47. Wu C.Y., Jan J.T., Ma S.H., Kuo C.J., Juan H.F., Cheng Y.S., Hsu H.H., Huang H.C., Wu D., Brik A., Liang F.S., Liu R.S., Fang J.M., Chen S.T., Liang P.H., and Wong C.H. Small molecules targeting severe acute respiratory syndrome human coronavirus. Proc. Natl. Acad. Sci. U.S.A. 101 (2004) 10012-10017
48. Xiao P.G., Xing S.T., and Wang L.W. Immunological aspects of Chinese medicinal plants as antiageing drugs. J. Ethnopharmacol. 38 (1993) 167-175
49. Yang Z.Y., Kong W.P., Huang Y., Roberts A., Murphy B.R., Subbarao K., and Nabel G.J. A DNA vaccine induces SARS coronavirus neutralization and protective immunity in mice. Nature 428 (2004) 561-564
50. Yi C.E., Ba L., Zhang L., Ho D.D., and Chen Z. Single amino acid substitutions in the severe acute respiratory syndrome coronavirus spike glycoprotein determine viral entry and immunogenicity of a major neutralizing domain. J. Virol. 79 (2005) 11638-11646
51. Yi L., Li Z., Yuan K., Qu X., Chen J., Wang G., Zhang H., Luo H., Zhu L., Jiang P., Chen L., Shen Y., Luo M., Zuo G., Hu J., Duan D., Nie Y., Shi X., Wang W., Han Y., Li T., Liu Y., Ding M., Deng H., and Xu X. Small molecules blocking the entry of severe acute respiratory syndrome coronavirus into host cells. J. Virol. 78 (2004) 11334-11339
52. Zhang M.M., Liu X.M., and He L. Effect of integrated traditional Chinese and Western medicine on SARS: a review of clinical evidence. World J. Gastroenterol. 10 (2004) 3500-3505
53. Zhang X.W., and Yap Y.L. Old drugs as lead compounds for a new disease? Binding analysis of SARS coronavirus main proteinase with HIV, psychotic and parasite drugs. Bioorg. Med. Chem. 12 (2004) 2517-2521
54. +-ATPase of the rabbit renal medulla and their diuretic action. Acta Pharmacol. Sin. 23 (1988) 17-20